by Roger Longman
If analysts didn't greet with hosannas the announcement of the proposed merger of the Hoechst AGand Rhone-Poulenc SA life sciences...
Outsourcing: Hoechst's New Approach to Cost Cutting
Eager to join the pharmaceutical elite, Hoechst needs to cut costs without creating more labor unrest. As it merges with Rhône-Poulenc into Aventis, HMR is outsourcing all US development to the CRO, Quintiles, looking to cut costs by $100 million over five years and provide a benchmark for the rest of HMR's worldwide development program. Moreover, both Quintiles and HMR hope to use the collaboration, perhaps in tandem with outside investors, to fund additional development projects; Quintiles would be assured the development work, and receive some of the drug's upside; HMR would be able to delay its own buy-in decisions until the projects had generated more actionable data. But the deal raises conflict-of-interest questions: will Quintiles' other clients shy away from a company with extra incentives to develop particular drugs-either those in which it has an equity interest or those of a client with whom it has a special relationship?
More from Business Strategy
• By
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
• By
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
More from In Vivo
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.